A Study of Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia
A Study of Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia
This study was to assess the safety of sequential intravenous (IV)/oral (PO) moxifloxacin (Avelox®) compared with sequential IV/PO levofloxacin (Levaquin®) in the treatment of elderly subjects (aged ≥ 65 years) with community-acquired pneumonia (CAP) who required initial IV therapy. This study also included an assessment of the clinical and bacteriologic effectiveness of both drugs.
Inclusion Criteria:
Exclusion Criteria: